<DOC>
	<DOC>NCT01954004</DOC>
	<brief_summary>This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.</brief_summary>
	<brief_title>Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Newly diagnosed (â‰¤6 months), untreated patients with histologically proven adenocarcinoma of the prostate that have the following characteristics. Clinically localized (no evidence on clinical or imaging studies of advanced disease). No hormonal therapy including LHRH (luteinizing hormonereleasing hormone) agonist or antagonist, antiandrogen, estrogens or exogenous androgens, when applicable. Sufficient amount of tissue remains from biopsy to perform genomic testing. Patients with a known history of hypogonadism</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>